Chromosome-level genome editing uncovers aneuploidy addiction in cancer

Siobhan O'Brien; Alice H Berger

doi:10.1016/j.crmeth.2023.100618

Chromosome-level genome editing uncovers aneuploidy addiction in cancer

Cell Rep Methods. 2023 Oct 23;3(10):100618. doi: 10.1016/j.crmeth.2023.100618. Epub 2023 Oct 10.

Authors

Siobhan O'Brien¹, Alice H Berger²

Affiliations

¹ Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
² Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Genome Sciences, University of Washington, Seattle, WA, USA. Electronic address: ahberger@fredhutch.org.

Abstract

Publishing in Science, Girish and colleagues achieve chromosome-level genome editing to reveal a requirement for aneuploidy in breast and melanoma cancers. Authors developed and leveraged ReDACT (restoring disomy in aneuploid cells using CRISPR targeting) to generate isogenic models of aneuploidy and demonstrate that some cancers are addicted to increased copy number of specific chromosome arms.

MeSH terms

Aneuploidy
Gene Editing*
Humans
Karyotype
Neoplasms* / genetics

Grants and funding

R37 CA252050/CA/NCI NIH HHS/United States